AI Startup Latest Funding Deal: Cohere raised $500M Series D round

Artificial Intelligence | Machine Learning | Machine Perception NOVIGENIX | Leader in Immuno-Transcriptomics for Cancer Detection

Biotechnology, Cancer Screening, Health Diagnostics, Oncology, Life Science Epalinges, VD, Switzerland

Artificial Intelligence | Machine Learning | Machine Perception

NOVIGENIX | Leader in Immuno-Transcriptomics for Cancer Detection

Biotechnology, Cancer Screening, Health Diagnostics, Oncology, Life Science

Epalinges, VD, Switzerland

Novigenix is an innovative Swiss molecular diagnostics company specializing in new generation blood tests for early detection of cancer. Colox®, our lead product is a proven molecular blood test designed to significantly reduce mortality from colorectal cancer through early detection and follow-up colonoscopy. Novigenix’s technology is based on a new generation of predictive gene expression profiles of circulating blood cells and concentration profile of tumor-derived protein markers in combination with state-of-the-art mathematical analytical models. Our predictive molecular signatures of biomarkers provide new and accurate solutions for the early detection of cancer. Generating insights from tumor-host interaction in order to detect cancer as early as possible and tailor the right treatment for the right patient. We are pioneering the field of immuno-transcriptomics with passion for improving health outcomes.